Penumbra (PEN) Stock Analysis & Winston Score

Penumbra makes medical devices used by doctors to treat serious conditions involving blood clots and bleeding in the brain and body. Its main products are tools that remove dangerous clots from blood vessels — a process called thrombectomy — as well as devices used in neurosurgery and vascular surgery. The company sells primarily to hospitals and surgical centers, competing in the medical device industry alongside larger players like Medtronic and Stryker. Penumbra earns revenue by selling its devices directly to hospitals, with no subscription model — each procedure requires its specialized, single-use tools. It operates mainly in the United States but has a growing international presence, and its strong 67% gross margin reflects the pricing power that comes from highly specialized, physician-trusted products. The key growth driver is expanding use of mechanical thrombectomy for stroke treatment, as clinical guidelines increasingly support the procedure, though the main risk is competition from larger, better-funded medical device companies entering the same market.